Cargando…

MLX plays a key role in lipid and glucose metabolism in humans: Evidence from in vitro and in vivo studies

BACKGROUND AND AIM: Enhanced hepatic de novo lipogenesis (DNL) has been proposed as an underlying mechanism for the development of NAFLD and insulin resistance. Max-like protein factor X (MLX) acts as a heterodimer binding partner for glucose sensing transcription factors and inhibition of MLX or do...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagarajan, Shilpa R., Livingstone, Eilidh J., Monfeuga, Thomas, Lewis, Lara C., Ali, Shahul Hameed Liyakath, Chandran, Anandhakumar, Dearlove, David J., Neville, Matt J., Chen, Lingyan, Maroteau, Cyrielle, Ruby, Maxwell A., Hodson, Leanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: W.B. Saunders 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687193/
https://www.ncbi.nlm.nih.gov/pubmed/37088121
http://dx.doi.org/10.1016/j.metabol.2023.155563
_version_ 1785151930415185920
author Nagarajan, Shilpa R.
Livingstone, Eilidh J.
Monfeuga, Thomas
Lewis, Lara C.
Ali, Shahul Hameed Liyakath
Chandran, Anandhakumar
Dearlove, David J.
Neville, Matt J.
Chen, Lingyan
Maroteau, Cyrielle
Ruby, Maxwell A.
Hodson, Leanne
author_facet Nagarajan, Shilpa R.
Livingstone, Eilidh J.
Monfeuga, Thomas
Lewis, Lara C.
Ali, Shahul Hameed Liyakath
Chandran, Anandhakumar
Dearlove, David J.
Neville, Matt J.
Chen, Lingyan
Maroteau, Cyrielle
Ruby, Maxwell A.
Hodson, Leanne
author_sort Nagarajan, Shilpa R.
collection PubMed
description BACKGROUND AND AIM: Enhanced hepatic de novo lipogenesis (DNL) has been proposed as an underlying mechanism for the development of NAFLD and insulin resistance. Max-like protein factor X (MLX) acts as a heterodimer binding partner for glucose sensing transcription factors and inhibition of MLX or downstream targets has been shown to alleviate intrahepatic triglyceride (IHTG) accumulation in mice. However, its effect on insulin sensitivity remains unclear. As human data is lacking, the aim of the present work was to investigate the role of MLX in regulating lipid and glucose metabolism in primary human hepatocytes (PHH) and in healthy participants with and without MLX polymorphisms. METHODS: PHH were transfected with non-targeting or MLX siRNA to assess the effect of MLX knockdown on lipid and glucose metabolism, insulin signalling and the hepatocellular transcriptome. A targeted association analysis on imputed genotype data for MLX on healthy individuals was undertaken to assess associations between specific MLX SNPs (rs665268, rs632758 and rs1474040), plasma biochemistry, IHTG content, DNL and gluconeogenesis. RESULTS: MLX knockdown in PHH altered lipid metabolism (decreased DNL (p < 0.05), increased fatty acid oxidation and ketogenesis (p < 0.05), and reduced lipid accumulation (p < 0.001)). Additionally, MLX knockdown increased glycolysis, lactate secretion and glucose production (p < 0.001) and insulin-stimulated pAKT levels (p < 0.01) as assessed by transcriptomic, steady-state and dynamic measurements. Consistent with the in vitro data, individuals with the rs1474040-A and rs632758-C variants had lower fasting plasma insulin (p < 0.05 and p < 0.01, respectively) and TG (p < 0.05 and p < 0.01, respectively). Although there was no difference in IHTG or gluconeogenesis, individuals with rs632758 SNP had notably lower hepatic DNL (p < 0.01). CONCLUSION: We have demonstrated using human in vitro and in vivo models that MLX inhibition favored lipid catabolism over anabolism and increased glucose production, despite increased glycolysis and phosphorylation of Akt, suggesting a metabolic mechanism that involves futile cycling.
format Online
Article
Text
id pubmed-10687193
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher W.B. Saunders
record_format MEDLINE/PubMed
spelling pubmed-106871932023-12-01 MLX plays a key role in lipid and glucose metabolism in humans: Evidence from in vitro and in vivo studies Nagarajan, Shilpa R. Livingstone, Eilidh J. Monfeuga, Thomas Lewis, Lara C. Ali, Shahul Hameed Liyakath Chandran, Anandhakumar Dearlove, David J. Neville, Matt J. Chen, Lingyan Maroteau, Cyrielle Ruby, Maxwell A. Hodson, Leanne Metabolism Article BACKGROUND AND AIM: Enhanced hepatic de novo lipogenesis (DNL) has been proposed as an underlying mechanism for the development of NAFLD and insulin resistance. Max-like protein factor X (MLX) acts as a heterodimer binding partner for glucose sensing transcription factors and inhibition of MLX or downstream targets has been shown to alleviate intrahepatic triglyceride (IHTG) accumulation in mice. However, its effect on insulin sensitivity remains unclear. As human data is lacking, the aim of the present work was to investigate the role of MLX in regulating lipid and glucose metabolism in primary human hepatocytes (PHH) and in healthy participants with and without MLX polymorphisms. METHODS: PHH were transfected with non-targeting or MLX siRNA to assess the effect of MLX knockdown on lipid and glucose metabolism, insulin signalling and the hepatocellular transcriptome. A targeted association analysis on imputed genotype data for MLX on healthy individuals was undertaken to assess associations between specific MLX SNPs (rs665268, rs632758 and rs1474040), plasma biochemistry, IHTG content, DNL and gluconeogenesis. RESULTS: MLX knockdown in PHH altered lipid metabolism (decreased DNL (p < 0.05), increased fatty acid oxidation and ketogenesis (p < 0.05), and reduced lipid accumulation (p < 0.001)). Additionally, MLX knockdown increased glycolysis, lactate secretion and glucose production (p < 0.001) and insulin-stimulated pAKT levels (p < 0.01) as assessed by transcriptomic, steady-state and dynamic measurements. Consistent with the in vitro data, individuals with the rs1474040-A and rs632758-C variants had lower fasting plasma insulin (p < 0.05 and p < 0.01, respectively) and TG (p < 0.05 and p < 0.01, respectively). Although there was no difference in IHTG or gluconeogenesis, individuals with rs632758 SNP had notably lower hepatic DNL (p < 0.01). CONCLUSION: We have demonstrated using human in vitro and in vivo models that MLX inhibition favored lipid catabolism over anabolism and increased glucose production, despite increased glycolysis and phosphorylation of Akt, suggesting a metabolic mechanism that involves futile cycling. W.B. Saunders 2023-07 /pmc/articles/PMC10687193/ /pubmed/37088121 http://dx.doi.org/10.1016/j.metabol.2023.155563 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nagarajan, Shilpa R.
Livingstone, Eilidh J.
Monfeuga, Thomas
Lewis, Lara C.
Ali, Shahul Hameed Liyakath
Chandran, Anandhakumar
Dearlove, David J.
Neville, Matt J.
Chen, Lingyan
Maroteau, Cyrielle
Ruby, Maxwell A.
Hodson, Leanne
MLX plays a key role in lipid and glucose metabolism in humans: Evidence from in vitro and in vivo studies
title MLX plays a key role in lipid and glucose metabolism in humans: Evidence from in vitro and in vivo studies
title_full MLX plays a key role in lipid and glucose metabolism in humans: Evidence from in vitro and in vivo studies
title_fullStr MLX plays a key role in lipid and glucose metabolism in humans: Evidence from in vitro and in vivo studies
title_full_unstemmed MLX plays a key role in lipid and glucose metabolism in humans: Evidence from in vitro and in vivo studies
title_short MLX plays a key role in lipid and glucose metabolism in humans: Evidence from in vitro and in vivo studies
title_sort mlx plays a key role in lipid and glucose metabolism in humans: evidence from in vitro and in vivo studies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687193/
https://www.ncbi.nlm.nih.gov/pubmed/37088121
http://dx.doi.org/10.1016/j.metabol.2023.155563
work_keys_str_mv AT nagarajanshilpar mlxplaysakeyroleinlipidandglucosemetabolisminhumansevidencefrominvitroandinvivostudies
AT livingstoneeilidhj mlxplaysakeyroleinlipidandglucosemetabolisminhumansevidencefrominvitroandinvivostudies
AT monfeugathomas mlxplaysakeyroleinlipidandglucosemetabolisminhumansevidencefrominvitroandinvivostudies
AT lewislarac mlxplaysakeyroleinlipidandglucosemetabolisminhumansevidencefrominvitroandinvivostudies
AT alishahulhameedliyakath mlxplaysakeyroleinlipidandglucosemetabolisminhumansevidencefrominvitroandinvivostudies
AT chandrananandhakumar mlxplaysakeyroleinlipidandglucosemetabolisminhumansevidencefrominvitroandinvivostudies
AT dearlovedavidj mlxplaysakeyroleinlipidandglucosemetabolisminhumansevidencefrominvitroandinvivostudies
AT nevillemattj mlxplaysakeyroleinlipidandglucosemetabolisminhumansevidencefrominvitroandinvivostudies
AT chenlingyan mlxplaysakeyroleinlipidandglucosemetabolisminhumansevidencefrominvitroandinvivostudies
AT maroteaucyrielle mlxplaysakeyroleinlipidandglucosemetabolisminhumansevidencefrominvitroandinvivostudies
AT rubymaxwella mlxplaysakeyroleinlipidandglucosemetabolisminhumansevidencefrominvitroandinvivostudies
AT hodsonleanne mlxplaysakeyroleinlipidandglucosemetabolisminhumansevidencefrominvitroandinvivostudies